Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 2 Interventional

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

ClinicalTrials.gov ID: NCT06990269

Public ClinicalTrials.gov record NCT06990269. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 1:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Masked, Placebo-Controlled Study of Subcutaneously Administered ADX-038 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Study identification

NCT ID
NCT06990269
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
ADARx Pharmaceuticals, Inc.
Industry
Enrollment
240 participants

Conditions and interventions

Interventions

  • ADX-038 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
60 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 9, 2025
Primary completion
Feb 27, 2030
Completion
Aug 29, 2030
Last update posted
Jun 15, 2026

2025 – 2030

United States locations

U.S. sites
19
U.S. states
8
U.S. cities
19
Facility City State ZIP Site status
ADARx Clinical Site Gilbert Arizona 85297 Recruiting
ADARx Clinical Site Phoenix Arizona 85020 Recruiting
ADARx Clinical Site Bakersfield California 93309 Recruiting
ADARx Clinical Site Beverly Hills California 90211 Recruiting
ADARx Clinical Site Huntington Beach California 93647 Recruiting
ADARx Clinical Site Poway California 92064 Recruiting
ADARx Clinical Site Orlando Florida 32806 Recruiting
ADARx Clinical Site Wildwood Florida 34785 Recruiting
ADARx Clinical Site Hagerstown Maryland 21740 Recruiting
ADARx Clinical Site Reno Nevada 89502 Recruiting
ADARx Clinical Site Erie Pennsylvania 16505 Withdrawn
ADARx Clinical Site Austin Texas 78705 Recruiting
ADARx Clinical Site Bellaire Texas 77401 Recruiting
ADARx Clinical Site Dallas Texas 75231 Recruiting
ADARx Clinical Site McAllen Texas 78503 Recruiting
ADARx Clinical Site Round Rock Texas 78681 Recruiting
ADARx Clinical Site San Antonio Texas 78340 Recruiting
ADARx Clinical Site The Woodlands Texas 77384 Recruiting
ADARx Clinical Site St. George Utah 84790 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06990269, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 15, 2026 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06990269 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →